Medincell to Showcase Pipeline at TD Cowen Healthcare Conference
Event summary
- Medincell will present at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, at 1:50 PM ET.
- Dr. Grace Kim, Chief Strategy Officer, U.S. Finance, will lead investor meetings.
- Teva's NDA for Olanzapine LAI was accepted by the FDA on February 20, 2026.
- Medincell's risperidone LAI (UZEDY®) received FDA approval for schizophrenia in April 2023 and Bipolar I Disorder in October 2025.
The big picture
Medincell's participation in the TD Cowen Healthcare Conference underscores its strategic focus on long-acting injectable treatments, a growing segment in the biopharmaceutical industry. The company's pipeline, particularly its risperidone and olanzapine LAI products, positions it as a key player in mental health treatments. The acceptance of Teva's NDA for Olanzapine LAI by the FDA marks a significant step in expanding its commercial portfolio.
What we're watching
- Regulatory Milestones
- The pace at which Medincell's pipeline advances through FDA approvals will determine its commercial traction.
- Partnership Dynamics
- How Medincell leverages its collaboration with Teva will impact its market penetration and revenue growth.
- Investor Sentiment
- The reception of Medincell's presentation at the TD Cowen conference may influence investor confidence and stock performance.
Related topics